Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

A Study In Healthy People To Investigate The Safety, Toleration And Time Course Of Blood Concentrations Of Multiple Doses Of PF-03654764, Given By Mouth

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: PF-03654764
Drug: placebo

First Posted Date: 2009-10-05

Last Posted Date: 2009-12-16

Lead Sponsor: Pfizer

Target Recruit Count: 36

Registration Number: NCT00989391

Locations: 🇸🇬
Pfizer Investigational Site, Singapore, Singapore

A Study In Healthy Volunteers To Estimate The Pharmacokinetics Of Four Modified-Release Formulations Of Dimebon (Latrepirdine)

Phase 1

Completed

Conditions: Alzheimer's Disease
Huntington Disease

Interventions: Drug: Dimebon MR2
Drug: Dimebon MR3
Drug: Dimebon IR Tablet
Drug: Dimebon MR1
Drug: Dimebon MR4

First Posted Date: 2009-10-02

Last Posted Date: 2010-01-12

Lead Sponsor: Pfizer

Target Recruit Count: 20

Registration Number: NCT00988624

Locations: 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States

Proof Of Mechanism Study To Determine Efficacy Of PF-04455242 In Blocking Spiradoline (PF-00345768) Stimulated Prolactin Release

Phase 1

Completed

Conditions: Bipolar Depression

Interventions: Drug: PF-04455242
Other: Placebo
Drug: spiradoline

First Posted Date: 2009-10-02

Last Posted Date: 2010-01-07

Lead Sponsor: Pfizer

Target Recruit Count: 24

Registration Number: NCT00988949

Locations: 🇸🇬
Pfizer Investigational Site, Singapore, Singapore

A Brief Study To Evaluate The Safety, Tolerability, And Blood Levels Of Multiple Doses Of PF-044467943 Or Placebo In Combination With Donepezil In Subjects With Mild To Moderate Alzheimer's Disease

Phase 1

Completed

Conditions: Alzheimer's Disease

Interventions: Drug: Placebo
Drug: PF-04447943

First Posted Date: 2009-10-02

Last Posted Date: 2020-11-19

Lead Sponsor: Pfizer

Target Recruit Count: 15

Registration Number: NCT00988598

Locations: 🇺🇸
Glendale Adventist Medical Center, Glendale, California, United States
🇺🇸
University of Florida - Center for Clinical Trials Research, Gainesville, Florida, United States
🇺🇸
MD Clinical, Hallandale Beach, Florida, United States

Filibuvir In Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Subjects

Phase 2

Completed

Conditions: Hepatitis
Hepatitis C

Interventions: Drug: Filibuvir
Drug: Placebo

First Posted Date: 2009-09-30

Last Posted Date: 2014-01-27

Lead Sponsor: Pfizer

Target Recruit Count: 288

Registration Number: NCT00987337

Locations: 🇪🇸
Pfizer Investigational Site, Sevilla, Spain

Effect of Aricept on Biomarkers (Acetylcholine, sAPP Alpha) In Cerebrospinal Fluid

Completed

Conditions: Alzheimer's Disease
Dementia

Interventions: Drug: donepezil (Aricept)
Drug: Placebo

First Posted Date: 2009-09-30

Last Posted Date: 2011-02-14

Lead Sponsor: Pfizer

Target Recruit Count: 12

Registration Number: NCT00987220

Locations: 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States

A Midazolam Drug Interaction Study With PF-04171327

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: PF-04171327 25 mg
Drug: Midazolam 2 mg

First Posted Date: 2009-09-30

Last Posted Date: 2009-12-08

Lead Sponsor: Pfizer

Target Recruit Count: 12

Registration Number: NCT00987038

Locations: 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States

Tanezumab In Osteoarthritis Of The Hip Or Knee

Phase 3

Terminated

Conditions: Osteoarthritis

Interventions: Biological: tanezumab 10 mg
Biological: tanezumab 5 mg
Other: placebo
Drug: oxycodone

First Posted Date: 2009-09-28

Last Posted Date: 2021-05-14

Lead Sponsor: Pfizer

Target Recruit Count: 614

Registration Number: NCT00985621

Locations: 🇺🇸
Achieve Clinical Research, Birmingham, Alabama, United States
🇺🇸
Alabama Orthopaedic Clinics, PC, Mobile, Alabama, United States
🇺🇸
Horizon Research Group, Inc., Mobile, Alabama, United States

and more 100 locations

A Trial Of CVX-060, An Anti-Angiogenic COVX-Body, In Combination With Sunitinib In Patients With Advanced Renal Cell Carcinoma

Phase 2

Terminated

Conditions: Solid Tumor

Interventions: Drug: Sunitinib
Drug: CVX-060 + sunitinib

First Posted Date: 2009-09-23

Last Posted Date: 2015-11-20

Lead Sponsor: Pfizer

Target Recruit Count: 34

Registration Number: NCT00982657

Locations: 🇺🇸
Premiere Oncology of Arizona, Scottsdale, Arizona, United States
🇺🇸
Premiere Oncology, A Medical Corporation, Santa Monica, California, United States
🇺🇸
Boston Baskin Cancer Foundation, Memphis, Tennessee, United States

and more 1 locations

A Trial Of SU14813 In Patients With Advanced Solid Malignancies

Phase 1

Completed

Conditions: Neoplasms
Solid Tumors

Interventions: Drug: SU014813

First Posted Date: 2009-09-23

Last Posted Date: 2011-08-08

Lead Sponsor: Pfizer

Target Recruit Count: 77

Registration Number: NCT00982267

Locations: 🇳🇱
Pfizer Investigational Site, Amsterdam, Netherlands

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy